GSK plc GSK.L
Composite 62/100; the shares have moved about 24% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Balance-sheet strength ranks 40/100 — a slight mark against it.
Income ranks 86/100 — a strong point in its favour. Growth ranks 76/100 — a strong point in its favour. Quality ranks 71/100 — a moderate point in its favour.
Balance-sheet strength ranks 40/100 — a slight mark against it. Momentum ranks 46/100 — a slight mark against it.
What the company does GSK plc researches, develops, and manufactures vaccines, specialty medicines (e.g., oncology, HIV, lupus), and general medicines (e.g., asthma, COPD) globally. Its pipeline targets unmet needs in oncology and inflammatory diseases, with recent focus on a £400m Cambridge cancer hub.
Key financials GSK reports strong profitability metrics: ROE 40.9%, ROA 10.0%, ROCE 20.1%, and net margins of 17.8%. Revenue growth is modest at 1.5%, but EPS growth is 8.4%. Debt/equity stands at 1.06, with interest coverage of 11.54 and a dividend yield of 3.4%.
Stock health The stock shows positive momentum: 3m +4.65%, 6m +10.45%, 12m +37.28%, though it remains -12.04% below its 52-week high. SIDERAVIA scores it "Excellent quality, fairly valued" (Overall 61.2), with high Quality (80.8) and Income (84.5) scores.
Price vs fair value GSK trades at a **discount** of 2.90% to our fair-value estimate and a **discount** of 6.70% to the analyst 12-month target. - Q2 2026 earnings beat and revenue growth cited (GuruFocus.com, Zacks) - $2.52B cost-saving plan funds pipeline expansion (GuruFocus.com) - £400m Cambridge cancer hub signals long-term R&D commitment (The Telegraph) - Analysts highlight accelerated pipeline progress (GuruFocus.com, MarketBeat)
Looking forward Forward P/E of 21.69 and EV/EBITDA of 9.34 suggest moderate valuation, while the dividend yield of 3.4% and payout ratio of 56.9% support income stability. Growth remains a focus amid pipeline advancements and cost efficiencies.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.